Last reviewed · How we verify
Genomic driven chemotherapy
Genomic-driven chemotherapy selects and administers chemotherapy agents based on individual tumor genomic profiling to optimize treatment efficacy and reduce toxicity.
Genomic-driven chemotherapy selects and administers chemotherapy agents based on individual tumor genomic profiling to optimize treatment efficacy and reduce toxicity. Used for Solid tumors with genomic profiling-guided chemotherapy selection.
At a glance
| Generic name | Genomic driven chemotherapy |
|---|---|
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This approach uses comprehensive genomic analysis of a patient's tumor to identify specific mutations, gene expression patterns, and molecular signatures that predict chemotherapy sensitivity. Treatment selection is then personalized based on these genomic findings, aiming to match the most effective chemotherapy agents to each patient's unique tumor biology, thereby improving response rates while minimizing unnecessary exposure to ineffective drugs.
Approved indications
- Solid tumors with genomic profiling-guided chemotherapy selection
Common side effects
- Chemotherapy-related toxicity (variable by selected agent)
- Hematologic toxicity
- Gastrointestinal toxicity
Key clinical trials
- Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests (PHASE3)
- ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer (PHASE3)
- Clonal Hematopoiesis in Giant Cell Arteritis
- Genotype-Driven Treatment of Advanced Non-small Cell Lung Cancer Based on mRNA Expression of ERCC1 & RRM1 as First-line Chemotherapy (PHASE2)
- Standard Neoadjuvant Chemotherapy Versus Genomic Driven Chemotherapy in Patients With Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Genomic driven chemotherapy CI brief — competitive landscape report
- Genomic driven chemotherapy updates RSS · CI watch RSS
- Gustave Roussy, Cancer Campus, Grand Paris portfolio CI